When it comes to managing Major Depressive Disorder (MDD), the challenge often lies in patients who do not fully respond to first-line treatments like SSRIs or SNRIs. For these patients, augmentation with atypical antipsychotics can be an effective strategy. But with several options available, which one should you choose?

The choice of atypical antipsychotic for MDD augmentation ultimately depends on the individual patient’s needs, the side effect profile of the medication, and any comorbid conditions.

Watch this brief video, which is a small excerpt from one of the chapters in our CME Academy’s inaugural course: Mastering Major Depressive Disorder Psychopharmacology.

Enroll here: psychiatryeducationforum.com/course/cme-1/